Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1238-1247

  Dizon, Don S ^a   Hensley, Martee L ^a   Poynor, Elizabeth A ^a   Sabbatini, Paul ^a   Aghajanian, Carol ^a   Hummer, Amanda ^a   Venkatraman, Ennapadam ^a   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; CANCER MODEL; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036499282     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1238     Document Type: Article

References (30)

1. Cancer statistics, 1999
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
4. Randomized phase III study of cisplatin/paclitaxel in optimal stage III epithelial ovarian cancer (a Gynecologic Oncology Group trial GOG 158)
5. First-line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer: A new standard of care?
6. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
7. Treatment of relapsed carcinoma of the ovary with cisplatin of carboplatin following initial treatment with these compounds
8. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
9. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
10. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
11. Phase II trial ofpaclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study
12. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin
13. Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube
14. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube
15. Clinical states in prostate cancer: Toward a dynamic model of disease progression
16. Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus Topotecan (T) in the treatment of patients with relapsed ovarian cancer
17. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer
18. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
19. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
20. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
21. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
22. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
23. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience
24. Clinical features of hypersensitivity reactions to carboplatin
25. New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] - Gynecologic Cancer Intergroup
26. Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group experience
27. Prognostic factors in advanced epithelial ovarian cancer: Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)
28. Prognostic factors in advanced ovarian carcinoma
29. Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy
30. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cispiatinor carboplatin-sensitive ovarian cancer